FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4246647562> ?p ?o ?g. }

• W4246647562 endingPage "22" @default.
• W4246647562 startingPage "22" @default.
• W4246647562 abstract "Background:Internal tandem duplications (ITDs) within the FMS-like tyrosine kinase 3 (FLT3) gene (FLT3-ITD) is a common driver mutation and confers a poor prognosis in patients (pts) with acute myeloid leukemia (AML) due to proliferative presentation, short remission durations and early relapse. The addition of midostaurin to induction therapy has become standard therapy in newly diagnosedFLT3-mutated (FLT3-mu) AML. Next-generation FLT3 inhibitors (FLT3i) as gilteritinib and quizartinib are more specific, more potent, and may have fewer toxicities associated with off-target therapies but are only available in clinical trials or for salvage therapy. Real-world experience in smaller academic institutions is scanty. Methods:We reviewedFLT3-ITD mu AML pts at our institution from October 2016-December 2019. FLT3i were given as a single agent or in combination with cytotoxic chemotherapy (CCT) or low intensity therapy (LIT) (hypomethylating agents). AllFLT3-ITD DNA was subjected to PCR amplification using primers targeting the juxtamembrane domain of FLT3, and products were analyzed by capillary electrophoresis. We analyzed the characteristics of these pts, responses to therapy, and outcomes. Results:Sixteen pts with newly diagnosedFLT3-ITD mu AML were identified. The median age was 47 years [range, 17-76 years] and the median follow-up was 9.3 months [range, 1.2-29.5 months]. The median time from AML diagnoses to FLT3 detection was 4 days [range, 3-5 days]. Patient characteristics are shown in Table 1. The most common co-occurring mutations wereNPM1(44%) andNRAS(31%); 2 pts (12%) had both mutations. Five pts (31%) received CCT and 11 pts (69%) received CCT+FLT3i. The most frequently used FLT3i was midostaurin 25 mg twice daily on days 8 through 21 (14 days) (10 pts, 63% of all pts); 1 pt received sorafenib (6% of all pts). The complete remission rate (CR) and the overall response rate (ORR) (CR+CR with incomplete hematologic recovery [CRi]) were 31% and 88%, respectively. The two pts who did not achieve a remission were older than 65 years. Among the pts who received CCT+FLT3i, CR and OOR were 50% and 100%, respectively. The median number of cycles to remission was 1 [range, 1-2 cycles], and the median number of consolidation cycles was 0 [range, 0-3 cycles]. Overall, the median duration of response in frontlineFLT3-ITD pts who did not receive allogeneic hematopoietic stem cell transplantation (Allo-HSCT) was 5 months [range, 1-9 months] (all of them received CCT+FLT3i). There was no statistically significant difference in response in pts with NPM1 mutation compared with pts with NRAS mutation (P=0.7), or with no additional mutations. Seven pts (44%) received an Allo-HSCT (6 after CCT+FT3i, and 1 after CCT alone): 2 (28%) from matched unrelated donor, 1 (14%) from a haploidentical transplant, 1 (14%) from dual cord transplant, and the remaining (44%) from matched related donors. Two patients relapsed after Allo-HSCT (28%). Both of these patients had received FLT3i before Allo-HSCT; one of the two relapsed pts received ivosidenib and azacitidine (IDH1 mutation) after Allo-HSCT, achieved remission then received the 2nd Allo-HSCT with subsequent remission. Two pts (29%) received maintenance therapy after Allo-HSCT, one with midostaurin, and the other with azacitidine + gilteritinib; both pts are still on remission (24 and 6 months after CR, respectively). All 7FLT3-ITD pts who did not receive Allo-HSCT relapsed. Gilteritinib was used as a single agent (n=3) or in combination with LIT (n=1) in these pts after relapse. CR rate was 25% and CRI 50%; one pt relapsed (33%). All pts who responded are still receiving gilteritinib. Conclusion:Combination of FLT3i based therapy with CCT is effective therapy inFLT3-ITD frontline pts in real-world setting. Duration of response is short in the absence of Allo-HSCT. Disclosures Cortes: Arog:Research Funding;Pfizer:Consultancy, Research Funding;Amphivena Therapeutics:Research Funding;Daiichi Sankyo:Consultancy, Research Funding;Astellas:Research Funding;Telios:Research Funding;Novartis:Consultancy, Research Funding;BioPath Holdings:Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding;Merus:Research Funding;Bristol-Myers Squibb:Research Funding;Takeda:Consultancy, Research Funding;Sun Pharma:Research Funding;BiolineRx:Consultancy, Research Funding;Immunogen:Research Funding;Jazz Pharmaceuticals:Consultancy, Research Funding." @default.
• W4246647562 created "2022-05-12" @default.
• W4246647562 creator A5015101485 @default.
• W4246647562 creator A5034221305 @default.
• W4246647562 creator A5039582413 @default.
• W4246647562 creator A5059747862 @default.
• W4246647562 creator A5062561099 @default.
• W4246647562 creator A5077470684 @default.
• W4246647562 date "2020-11-05" @default.
• W4246647562 modified "2023-10-15" @default.
• W4246647562 title "Outcomes of FLT3-Mutated Acute Myeloid Leukemia Patients: A Single Center Real-World Experience" @default.
• W4246647562 doi "https://doi.org/10.1182/blood-2020-135940" @default.
• W4246647562 hasPublicationYear "2020" @default.
• W4246647562 type Work @default.
• W4246647562 citedByCount "0" @default.
• W4246647562 crossrefType "journal-article" @default.
• W4246647562 hasAuthorship W4246647562A5015101485 @default.
• W4246647562 hasAuthorship W4246647562A5034221305 @default.
• W4246647562 hasAuthorship W4246647562A5039582413 @default.
• W4246647562 hasAuthorship W4246647562A5059747862 @default.
• W4246647562 hasAuthorship W4246647562A5062561099 @default.
• W4246647562 hasAuthorship W4246647562A5077470684 @default.
• W4246647562 hasConcept C126322002 @default.
• W4246647562 hasConcept C141071460 @default.
• W4246647562 hasConcept C143998085 @default.
• W4246647562 hasConcept C2776481607 @default.
• W4246647562 hasConcept C2776694085 @default.
• W4246647562 hasConcept C2778336483 @default.
• W4246647562 hasConcept C2778729363 @default.
• W4246647562 hasConcept C71924100 @default.
• W4246647562 hasConceptScore W4246647562C126322002 @default.
• W4246647562 hasConceptScore W4246647562C141071460 @default.
• W4246647562 hasConceptScore W4246647562C143998085 @default.
• W4246647562 hasConceptScore W4246647562C2776481607 @default.
• W4246647562 hasConceptScore W4246647562C2776694085 @default.
• W4246647562 hasConceptScore W4246647562C2778336483 @default.
• W4246647562 hasConceptScore W4246647562C2778729363 @default.
• W4246647562 hasConceptScore W4246647562C71924100 @default.
• W4246647562 hasIssue "Supplement 1" @default.
• W4246647562 hasLocation W42466475621 @default.
• W4246647562 hasOpenAccess W4246647562 @default.
• W4246647562 hasPrimaryLocation W42466475621 @default.
• W4246647562 hasRelatedWork W2091720821 @default.
• W4246647562 hasRelatedWork W2270007049 @default.
• W4246647562 hasRelatedWork W2353335878 @default.
• W4246647562 hasRelatedWork W2377618888 @default.
• W4246647562 hasRelatedWork W2388730008 @default.
• W4246647562 hasRelatedWork W2406230970 @default.
• W4246647562 hasRelatedWork W2889180997 @default.
• W4246647562 hasRelatedWork W3031299550 @default.
• W4246647562 hasRelatedWork W3114061532 @default.
• W4246647562 hasRelatedWork W4303832889 @default.
• W4246647562 hasVolume "136" @default.
• W4246647562 isParatext "false" @default.
• W4246647562 isRetracted "false" @default.
• W4246647562 workType "article" @default.